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Abstract
Background: Sustained DMARD-free remission (SDFR) is increasingly achievable. The pathogenesis underlying
SDFR development is unknown and patient characteristics at diagnosis poorly explain whether SDFR will be
achieved. To increase the understanding, we studied the course of disease activity scores (DAS) over time in
relation to SDFR development. Subsequently, we explored whether DAS course could be helpful identifying RA
patients likely to achieve SDFR.
Methods: 772 consecutive RA patients, promptly treated with csDMARDs (mostly methotrexate and treat-to-target
treatment adjustments), were studied for SDFR development (absence of synovitis, persisting minimally 12 months
after DMARD stop). The course of disease activity scores (DAS) was compared between RA patients with and
without SDFR development within 7 years, using linear mixed models, stratified for ACPA. The relation between
4-month DAS and the probability of SDFR development was studied with logistic regression. Cumulative incidence
of SDFR within DAS categories (< 1.6, 1.6–2.4, 2.4–3.6, ≥ 3.6) at 4 months was visualized using Kaplan-Meier curves.
Results: In ACPA-negative RA patients, those achieving SDFR showed a remarkably stronger DAS decline within the
first 4 months, compared to RA patients without SDFR; − 1.73 units (95%CI, 1.28–2.18) versus − 1.07 units (95%CI,
0.90–1.23) (p < 0.001). In APCA-positive RA patients, such an effect was not observed, yet SDFR prevalence in this
group was low. In ACPA-negative RA, DAS decline in the first 4 months and absolute DAS levels at 4 months
(DAS4 months) were equally predictive for SDFR development. Incidence of SDFR in ACPA-negative RA patients was
high (70.2%) when DAS4 months was < 1.6, whilst SDFR was rare (7.1%) when DAS4 months was ≥ 3.6.
Conclusions: In ACPA-negative RA, an early response to treatment, i.e., a strong DAS decline within the first
4 months, is associated with a higher probability of SDFR development. DAS values at 4 months could be useful for
later decisions to stop DMARDs.
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Key messages
– Despite RA’s chronic character, sustained DMARD-
free remission is increasingly achievable in both in
ACPA-negative and ACPA-positive RA. The bio-
logical pathways underlying SDFR-development are
poorly understood. Additionally, identified baseline
characteristics poorly explain which RA patients are
able to achieve SDFR over time.
– This is the first study scoping beyond baseline
characteristics to understand SDFR, by exploring the
course of disease activity scores (DAS) over time in
relation to achieving SDFR.
– This study showed that early response to treatment,
i.e., significant decrease in DAS within the first
4 months after diagnosis, is associated with
achieving SDFR in ACPA-negative RA. DAS levels
in the first 4 months were predictive for SDFR de-
velopment, and incidence of SDFR was high when
DAS < 1.6 at 4 months, whilst SDFR was rare when
DAS was ≥ 3.6 at 4 months.
– Our findings suggest that early reduction of
inflammation can influence chronification in ACPA-
negative RA, i.e., the development of SDFR, and that
the “window of opportunity” might expand to the
early phase after initiation of DMARD treatment.
– Evaluation of early response to treatment might be
helpful for clinicians in later decisions to stop
DMARDs in ACPA-negative RA.
Background
Rheumatoid arthritis (RA) is regarded as a chronic dis-
ease, requiring life-long treatment [1]. Nonetheless, ta-
pering and sustained cessation of DMARDS, termed
sustained DMARD-free remission (SDFR), is increasingly
achievable in ACPA-negative and ACPA-positive RA [2,
3]. Achieving SDFR has been shown to associate with
symptom resolution and normalization of functional
ability [2]. Also, it limits prolonged exposure to side-
effects and unnecessary healthcare costs [4]. Currently,
SDFR is the best proxy for disease resolution (or “cure”)
in RA [5].
So far, little is known about the biological pathways under-
lying the development of this favorable long-term outcome
[6]. Several patient characteristics at time of diagnosis have
been studied [2, 7–10], but these poorly explained SDFR de-
velopment. Only the presence of auto-antibodies was repeat-
edly found to be unfavorable for SDFR development [2, 7, 8,
11–13]. This relates to the existence of two subsets of RA pa-
tients, in which those with auto-antibodies have a lower cap-
ability of achieving SDFR [3, 12]. Different mechanisms
underlying SDFR development might be involved in ACPA-
positive and ACPA-negative RA patients. It has been sug-
gested that SDFR development in ACPA-negative RA
patients solely reflects spontaneous resolution of inflamma-
tion in patients misclassified as RA (e.g., reactive arthritis or
osteoarthritis). Yet, since SDFR is also achievable in ACPA-
positive RA, it cannot solely depend on misclassification of
disease. Furthermore, the finding that SDFR has become
more frequent with improved treatment strategies, also in
ACPA-negative RA [2], indicates that SDFR is a real disease
outcome in RA patients that otherwise would have had a
chronic disease.
Measures of inflammation (joint counts, acute phase reac-
tants, MRI-detected joint inflammation) at the time of diag-
nosis appeared non-informative in distinguishing which RA
patients are likely to achieve SDFR [2, 7–10, 13, 14]. Poten-
tially, differences in biological pathways leading towards dis-
ease resolution, i.e., SDFR, are not detectable at baseline, but
might unfold later on. Then, not disease characteristics at
diagnosis, but during the disease course might relate to SDFR
development. It could be hypothesized that timely suppres-
sion of inflammation with DMARD treatment can influence
chronicity of disease, i.e., benefit SDFR development. How-
ever, there is currently no longitudinal data available which
could provide insight in the course of inflammation over
time and SDFR development. It has been reported that
timely response to treatment is beneficial for other outcomes
in RA, like sustained remission and radiographic progression
[15–19]. Potentially, timely response to DMARD treatment
can also benefit SDFR development in RA patients.
Difficulty in identifying RA patients that are highly
likely to achieve SDFR makes clinicians ambiguous in
their decisions to discontinue DMARD treatment.
EULAR guidelines suggest to consider tapering, but do
not provide further practical guidance for treatment dis-
continuation [4, 20]. Because discontinuation of DMAR
D treatment in clinical practice is currently based on
trial and error, it is essential to attain further knowledge
on SDFR development in both ACPA-positive and
ACPA-negative RA. Effective prediction of successful
achievement of SDFR will safeguard patients from flare,
which has indisputable impact on health status, psycho-
logical health, and social life [21, 22].
With the ultimate aim to increase the understanding of
SDFR development in RA, and acknowledging that mea-
sures of inflammation at the time of diagnosis are of little
importance for this outcome, we explored the relation be-
tween disease activity over time with achieving SDFR.
Subsequently, we explored whether information on the
course of disease activity may be relevant for distinguish-
ing which RA patients are more likely to achieve SDFR.
Patients and methods
Patient selection
Patients for this study were obtained from the Leiden
Early Arthritis Clinic (EAC), which has been previously
described [23]. In short, the Leiden EAC is an inception
Verstappen et al. Arthritis Research & Therapy          (2020) 22:276 Page 2 of 11
cohort, including all patients presenting with recent on-
set arthritis with a symptom duration ≤ 2 years. For this
study, all consecutive RA patients fulfilling the 1987
and/or 2010 criteria [24, 25] and promptly treated with
conventional DMARDs, were evaluated. RA was evalu-
ated after 1 year of follow-up and stringently defined by
a clinical diagnosis by an experienced rheumatologist
plus fulfillment of 1987/2010 criteria. Patients diagnosed
with conditions other than RA (e.g., reactive arthritis,
psoriatic arthritis, inflammatory osteoarthritis) during
follow-up were excluded. Although the cohort started in
1993, prompt DMARD treatment, and subsequent taper-
ing when remission was achieved, became common
since 1999; therefore, RA patients that were consecu-
tively included from 1999 onwards were used. Patients
who participated in clinical trials (and therefore not rou-
tinely treated) were excluded.
Follow-up
Research visits took place at baseline, after 4 months
and annually afterwards. During these visits, joint counts
were performed, laboratory measurements done (serum
samples tested for CRP level, ESR, IgG ACPA (ELISA
CCP (anti-CCP2), Phadia, Nieuwegein, the Netherlands),
and IgM rheumatoid factor (RF; in-house ELISA [26]))
and questionnaires filled out. Four-component formula
was used to calculate DAS [27]. Follow-up duration dif-
fered among RA patients (median 7.0 years, IQR, 4.1–
11.6 years), which is inherent to the design of an obser-
vational cohort. All available follow-up data was studied,
but SDFR achievement was assessed after 7 years.
Treatment
In brief, all RA patients were promptly treated with
csDMARDs after diagnosis, in which methotrexate was
the first choice. DAS-steered treatment adjustments be-
came common since 2005. When treatment with initial
conventional DMARD (csDMARD) failed, another
csDMARD was initiated or added. A biological DMARD
(bDMARD) was allowed when RA patients failed ≥ 2
csDMARDs. If clinical remission (defined as DAS < 2.4)
was sustained, and clinical synovitis was absent, treat-
ment could be tapered and eventually discontinued. De-
cisions on cessation of DMARDs were taken in shared-
decision making between rheumatologists and patients.
Outcome
Sustained DMARD-free remission (SDFR) was defined
as the absence of clinical synovitis (swollen joints at
physical examination) after discontinuation of DMARD
treatment (including systemic and intra-articular corti-
costeroids) that persisted for the entire follow-up there-
after and this follow-up should be ≥ 1 year. This
stringent definition was chosen to ensure sustainability.
Medical files were studied on occurrence of SDFR until
May 2017.
Using all available data up to 7 years of follow-up, two
outcome groups were discerned; RA patients achieving
SDFR within 7 years, and those who did not. RA patients
achieving SDFR after 7 years were regarded as non-
SDFR. Additionally, to be stringent in sustainability of
the outcome, RA patients experiencing a flare (defined
as recurrence of clinical synovitis) after SDFR develop-
ment were also included in the non-SDFR group.
Statistical analysis
Baseline characteristics were compared using t test,
Mann-Whitney U test and Fisher’s exact test as
appropriate.
The course of DAS over 7 years was compared between
the SDFR group and non-SDFR group, using linear mixed
models. Splines were used to model the non-linear rela-
tion between DAS and time [28], with knots at baseline, 4
m, 12m, and for every single year after, based on the
structured research visits. Analyses were repeated for the
individual DAS components (SJC, TJC, ESR, VAS). Add-
itionally, analyses were stratified for ACPA status.
Subsequently, to evaluate whether DAS scores were
predictive for SDFR development within 7 years, the as-
sociations between DAS decline between 0 and 4 months
(ΔDAS0–4m) and absolute 4-month DAS levels
(DAS4 months) with SDFR development were explored
using logistic regression models, with SDFR develop-
ment as dependent variable. Baseline characteristics were
added to construct multivariable models. Analyses were
stratified for ACPA. Thereafter, to incorporate differ-
ences in a follow-up, and time to SDFR development,
Kaplan-Meier curves were constructed and used to de-
termine cumulative incidence of SDFR within 7 years for
different DAS categories at 4 months. DAS4 months levels
were categorized as follows; < 1.6, 1.60–2.39, 2.4–3.59,
and ≥ 3.6.
Two sensitivity analyses were done. First, patients
achieving SDFR after 7 years were also included in the
SDFR group, i.e., grouping all RA patients ever achieving
SDFR together, and LMM analysis were repeated. Simi-
larly, patients with a flare after 7 years, but achieving
SDFR< 7 years, were included in the SDFR group to
compare results.
The second sub-analyses concerned the evaluation of
missing data for the analysis on the predictive ability of
the DAS4 months. So far, only complete data was used
(n = 365). In 177 RA patients, the DAS4 months was in-
complete due to missing DAS components, that were
unrecorded during research visits, and in 230 RA pa-
tients DAS4 months was missing completely due to un-
attended visits. Baseline characteristics of patients with
missing DAS4 months did not remarkably differ from
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those with complete DAS4 months (n = 365) (supplemen-
tary Table S1). Missing DAS scores or DAS components
were imputed using chained equations (MICE) [29].
Point estimates and confidence intervals were pooled ac-
cording to Rubin’s rules across 30 imputations.
STATA (V12.0), SPSS (V.25.0), and R (V3.5.2) were used.
P values< 0.05 were considered statistically significant.
Results
Study population
Between January 1999 and December 2014, 1109 RA pa-
tients were consecutively included in the EAC and
promptly treated with csDMARDs. 337 patients were ex-
cluded due to concomitant participation in a clinical
trial. Consequently, 772 RA patients were included in
this study (supplementary Figure S2), which all had a
clinical diagnosis of RA and fulfilled the 1987 and/or
2010 criteria. Compared to the study population, pa-
tients that were excluded because of trial participation
had higher disease activity and higher rate of ACPA
positivity at baseline (supplementary Table S3).
Of the 722 included RA patients, 45% was ACPA-
positive, of the 400 ACPA-negative patients, 24.3% were
positive for rheumatic factor (RF).
Within the total study population, 149 RA patients
achieved SDFR within 7 years after diagnosis (SDFR
group), after median 3.2 years (IQR, 2.0–4.6 years).
Twenty-four patients achieved SDFR after 7 years (me-
dian 9.6 years (IQR, 7.4–10.5)) and were included in the
non-SDFR group, together with the 588 patients who
never achieved SDFR during follow-up. Additionally, 11
patients flared after SDFR development; these flares oc-
curred relatively late after achieving SDFR (median 2.6
years (IQR, 2.3–5.5)). These patients were included in
the non-SDFR group to strictly define the SDFR group.
Baseline characteristics are presented in Table 1.
Disease activity scores over time in relation to SDFR
Baseline DAS was not different between the SDFR and
non-SDFR groups (Fig. 1, supplementary Table S4).
However, the SDFR group showed a stronger decline in
DAS within the first 4 months; − 1.59 units (95%CI;
1.24–1.95) versus − 0.96 units (95%CI, 0.85–1.07) in the
non-SDFR-group (p < 0.001) (Fig. 1). No significant dif-
ferences in DAS course after 4 months were seen be-
tween both groups (supplementary Table S4).
DAS components over time in relation to SDFR
Analyses were repeated for the individual DAS compo-
nents. RA patients achieving SDFR had a statistically sig-
nificant stronger decline in SJC, TJC, and ESR within the
first 4 months, compared to RA patients who did not
achieve SDFR (p < 0.001) (Fig. 2, supplementary Table
S5). Course of VAS did not significantly differ between
both groups.
Stratification for ACPA
In ACPA-negative RA patients, 31.8% (127/400) achieved
SDFR within 7 years, after a median 3.2 years of follow-up
(IQR, 1.7–4.5 years). LMM analysis in ACPA-negative RA
showed that patients achieving SDFR had a stronger de-
cline in DAS within the first 4 months; − 1.73 units
(95%CI; -2.18, -1.28) versus − 1.07 units (95%CI; − 1.23, −
0.90) (p < 0.001) (Fig. 1, supplementary Table S4). In the
interval from 4 to 12 months, the non-SDFR group
showed a slightly stronger decline, suggestive of a delayed
DAS response compared to the SDFR group.
ACPA-positive RA patients achieved SDFR in 4.3%
(15/348), median 3.3 years after diagnosis (IQR, 1.9–4.8
years). In ACPA-positive RA, both groups showed a de-
cline in DAS within the first 4 months (Fig. 2), but this
decline was not stronger in the SDFR group; − 0.88 units
(95%CI, − 1.03, − 0.73) versus − 0.96 units (95%CI; −
Table 1 Baseline characteristics of the study population
Total study population (n = 772) non-SDFR group (n = 623) SDFR group (n = 149)
Age (years), mean (SD) 58.0 (15.4) 56.6 (15.2) 64.0 (14.9)
Females, n (%) 528 (68.4) 435 (70.7) 88 (59.1)
ACPA positivity+ n (%) 348 (45.1) 333 (54.1) 15 (10.1)
Symptom duration at diagnosis+
(≤ 12 vs > 12 weeks), n (%)
257 (33.5) 207 (33.2) 50 (33.6)
DAS at baseline+, med (IQR) 3.10 (2.52–3.72) 3.10 (2.51–3.69) 3.10 (2.55–3.91)
SJC at baseline+, (0–44), med (IQR) 6 (3–11) 6 (3–11) 8 (4–13)
TJC at baseline+, (0–53), med (IQR) 6 (4–9) 6 (4–10) 6 (4–9)
ESR+ (mm/h), med (IQR) 29 (14–45) 29 (14–45) 29 (14–47)
VAS+ (0–100mm), med (IQR) 40 (20–60) 41 (20–60) 38 (20–60)
Legend: Baseline characteristics of the patients with RA in the total study population and subgroups according to achievement of sustained DMARD-free remission
(SDFR) during 7 years of follow-up. +ACPA status was missing in 24 patients. Symptom duration was missing in 50 patients. DAS at baseline was missing in 124
patients. DAS components SJC, TJC, ESR, and VAS were missing in 29, 124, 8, and 101 patients
DAS disease activity score based on swollen joint count (44 joints), tender joint count (53 joints), ESR, and pain; SJC swollen joint count; TJC tender joint count, ESR
estimated sedimentation rate; VAS visual analog scale, ACPA anti-citrullinated protein antibody
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Fig. 1 (See legend on next page.)
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1.76, − 0.15). Later time intervals did not show large dif-
ferences (supplementary Table S4). Notably, SDFR
prevalence in the ACPA-positive RA group was low,
which might have limited the power to detect differences
in ACPA-positive patients achieving SDFR.
Early DAS response as a predictor for achieving SDFR
Subsequently, we explored whether DAS levels at 4 months
can be used to predict SDFR development within 7 years. In
uni- and multivariable logistic regression analysis in ACPA-
negative RA (n = 171), a stronger decrease in DAS between
baseline and 4 months (ΔDAS0–4m), i.e., a more negative
ΔDAS0–4m, was associated with an increased chance of SDFR
development. Inversely, a smaller decline in DAS decreased
the chance of SDFR: OR0.58 (95%CI; 0.42–0.80) for one
point less decline in DAS (Table 2, supplementary Table S6).
Since DAS at one time point is more practical for use
in clinical practice than a DAS change over time, abso-
lute DAS levels at 4 months (DAS4 months) were studied,
and included in the model instead of ΔDAS0–4m. In
ACPA-negative RA patients, absolute DAS4 months was
predictive for SDFR development, OR0.44 (95%CI, 0.29–
0.68), in a model that included baseline DAS (this
(See figure on previous page.)
Fig. 1 Course of DAS over time for the SDFR and non-SDFR group in the total RA population studied, and for ACPA-negative RA and ACPA-
positive RA separately. Legend: Course of DAS over time of patients achieving sustained DMARD-free remission (SDFR) within 7 years of follow-up
(n = 149), and those not (n = 623). In ACPA-positive patients, the line of the SDFR group was restricted to 5 years of follow-up because of
insufficient data thereafter. Statistically significant differences in course of DAS over time, between the SDFR group and non-SDFR group, were
indicated by with *. ACPA anti-citrullinated protein antibody, DAS disease activity scores, RA rheumatoid arthritis, SDFR sustained
DMARD-free remission
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Fig. 2 Course of DAS components over time for the SDFR- and non-SDFR group in all RA patients. Legend: Course of DAS components over time
of patients achieving sustained DMARD-free remission (SDFR) within 7 years of follow-up, and those not. Statistically significant differences in
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analysis still mimicked ΔDAS0–4 m), and also in a model
without baseline DAS, OR0.51 (95%CI, 0.35–0.75)
(Table 2, supplementary Table S6). Thus, ΔDAS0–4m
and DAS4 months were equally predictive for SDFR
development.
Figure 3 depicts the inverse relation between
DAS4 months and the predicted probabilities of achieving
SDFR, based on the multivariable logistic model without
baseline DAS.
Subsequently, Kaplan-Meier curves were constructed,
categorizing patients in 4 groups based on DAS4 months (<
1.6, 1.60–2.39, 2.4–3.59, ≥ 3.6) (Fig. 4). The cumulative in-
cidence among ACPA-negative RA patients with
DAS4 months < 1.6 was high (70.2%), whereas SDFR was
rare (7.1%) among patient with DAS4 months ≥ 3.6.
In ACPA-positive RA (n = 169), incidence of SDFR de-
velopment was low, and neither ΔDAS0–4m nor
DAS4 months was associated with SDFR development
(supplementary Table S6). The ACPA-positive RA pa-
tients achieving SDFR (n = 15) had a median DAS4 months
of 2.22 units (IQR, 2.19–2.37) with a median ΔDAS0–4m
of − 0.60 units (IQR, − 0.96, − 0.50). This did not signifi-
cantly differ from the ACPA-positive RA patients not
achieving SDFR; DAS4 months 2.22 units (IQR, 1.52–2.84)
and ΔDAS0–4m − 0.80 units (IQR, − 1.50, − 0.05).
Sensitivity analyses
Including patients achieving SDFR after 7 years (n = 24)
in the SDFR group, instead of the non-SDFR group, and
repeating the LMM yielded similar results on the course
of DAS between the two groups. Including patients that
flared after 7 years, but achieved SDFR< 7 years, in the
SDFR group also yielded similar results (supplementary
Tables S7 and S8).
Imputing the missing DAS data and repeating logis-
tic regression analyses and Kaplan-Meier analysis
yielded similar results (supplementary Table S9 and
Figure S10).
Discussion
SDFR, the sustained absence of clinical synovitis after
DMARD stop, reflects resolution of disease chronicity
and is currently the best possible long-term outcome for
RA. The chance to achieve this outcome is not well pre-
dicted by DAS at diagnosis but, as we demonstrated
here, is strongly associated with a rapid decline in DAS
in the first months after diagnosis and treatment start.
The notion that an early response to treatment is im-
portant for this long-term outcome suggests that timely
reduction of inflammation might confine chronification
in RA. Moreover, the comprehension that DAS levels at
4 months are predictive for the ability to achieve SDFR
over time in ACPA-negative RA patients can be import-
ant for clinicians, as it can contribute to the selection of
RA patients eligible for DMARD discontinuation. Espe-
cially 4-month DAS of < 1.6 or ≥ 3.6 may be considered
as most relevant, as these values were associated with
high and low incidence rates of SDFR, respectively.
The importance of early clinical response for out-
come in RA has been emphasized in previous re-
search [15–19]. A relation between early clinical
response and achieving low disease activity or remis-
sion after 6 or 12 months [15, 16, 18], thus short-
term outcomes, has been reported. Following, early
remission appeared beneficial for sustainability of re-
mission during DMARD-treatment as reported previ-
ously [19]. However, limited data is available on the
association with long-term outcomes in RA, such as
SDFR. The IMPROVED study [11] reported early re-
mission to be associated with a higher occurrence of
SDFR in UA-/RA-population. However, patients
achieving DAS remission at 4 months were treated
differently from those who did not achieve remission
at 4 months. This makes comparison of SDFR, among
those with and without early remission, conditional.
In our study, we expand on previous findings with
more detailed analyses on time courses and on
Table 2 Association of DAS0–4m and DAS4m with SDFR development within 7 years in ACPA-negative RA
Multivariable logistics regression models
OR (95%CI) p value OR (95%CI) p value OR (95%CI) p value
Age (years) 1.01 (0.99–1.04) 0.37 1.02 (0.99–1.04) 0.38 1.02 (0.99–1.05) 0.13
Gender (male) 1.65 (0.80–3.39) 0.18 1.40 (0.66–2.97) 0.31 1.25 (0.61–2.57) 0.55
Symptom duration at diagnosis (≤ 12 weeks vs. > 12 weeks) 0.93 (0.45–1.88) 0.82 0.87 (0.42–1.79) 0.70 0.97 (0.49–1.93) 0.92
Baseline DAS – 1.44 (1.00–2.08) 0.05 –
DAS4 months – 0.44 (0.29–0.68) < 0.01 0.51 (0.35–0.75) < 0.01
ΔDAS0–4m 0.58 (0.42–0.80) < 0.01 – –
Legend: Multivariable logistic regression models in ACPA-negative RA (n = 184) with SDFR (yes/no) as dependent outcome variable. Multivariable analysis showed
DAS levels at 4 months (DAS4 months) were as predictive of SDFR as decrease in ΔDAS0–4m, with and without incorporation of baseline DAS in the model
DAS disease activity score, BL baseline, CI confidence interval
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possible clinical utility. Also, in our study, all patients
were treated conform current guidelines, comparable
to most clinical practice.
The finding that DAS change within the first months
is related to achieving SDFR, suggests that biological
pathways relevant for SDFR development evolve in the
earliest phase after diagnosis and treatment initiation in
ACPA-negative RA. Timely suppression of inflammation
might confine chronification. According to the “window
of opportunity”, disease processes mature over time and
early intervention is therefore more effective. The
present results may suggest that the timeline of the
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window of opportunity does not comprise the period be-
fore diagnosis but also extends in the early period dir-
ectly after diagnosis and treatment initiation in ACPA-
negative RA. To unravel such mechanisms, further stud-
ies could focus on the early phase after start of DMARD
treatment. Interestingly, several cytokines were recently
observed to be increased in patients that achieved SDFR
over time [30], such observations now merits further
longitudinal studies in samples repeatedly taken early
after treatment start.
Our findings were inconclusive in ACPA-positive RA
since the low SDFR prevalence in these patients limited
the power for our analysis. However, no clear tendency
towards an effect was observed. Whether a higher
SDFR prevalence in our ACPA-positive group would
have resulted in a significant effect remains warranted.
In our study, tapering was non-protocolized (and based
on shared decision making), which might have underes-
timated the SDFR prevalence. This underestimation
may be more present in ACPA-positive RA if either pa-
tients or rheumatologists more frequently did not want
to stop DMARDs because of the believe that ACPA-
positive RA is a more severe disease and cessation
would be unsuccessful [31]. Nevertheless, previous re-
search, applying protocolized tapering, also showed
SDFR prevalence in ACPA-positive RA was low [32].
Following, ACPA positivity seems to increase flare rate
after achieving DMARD-free remission [33, 34].
Altogether this suggests that pathways leading towards
SDFR might be different for ACPA-positive and ACPA-
negative RA. Potentially, the hypothesized “extension”
of the window of opportunity does not hold for ACPA-
positive RA patients since these have a longer pre-
arthritis phase [35] and, possibly, disease processes have
fully matured at the time of diagnosis and initiation of
treatment. Yet, this remains subject to future research.
It has been suggested that SDFR development in
ACPA-negative patients solely reflects spontaneous
resolution of inflammation in patients misclassified as
RA. To rule out this possibility, we only analyzed pa-
tients who had a clinical RA diagnosis after 1 year of
follow-up, and patients diagnosed with conditions
other than RA during follow-up were excluded. Add-
itionally, all included patients fulfilled the 1987 and/
or 2010 criteria, in which more than half (58%) of the
ACPA-negative patients even fulfilled both criteria.
Thus, all included patients had both a clinical diagno-
sis of RA and fulfilled classification criteria, which are
meant for research as presented here. Additionally, of
the 127 ACPA-negative RA patients who achieved
SDFR, 16% was RF-positive and 22% erosive at base-
line, supporting that the ACPA-negative RA SDFR
group did not solely contain patients with least severe
RA.
Also within RA, it has been implied that SDFR as
treatment outcome is non-existent, but reflects spontan-
eous remission [36], in which “early response” could be
regarded part of this natural course. Our study was ob-
servational in nature, and did not include a placebo arm,
and unfortunately is unable to address this question.
However, it is known that DAS levels most prominently
decline in the first months after treatment initiation
[28]. The DAS course in untreated RA patients is rela-
tively unexplored.
Currently, treatment and tapering strategies are for-
mally similar for ACPA-positive and ACPA-negative RA
patients [4, 20], and discontinuation of treatment is
based on trial and error. Our findings might aid to con-
struct more substantiated discontinuation strategies,
stratified for ACPA status. We showed that ACPA-
negative RA patients who rapidly achieve DAS remission
< 1.6 have a considerably chance of future successful ta-
pering and cessation of DMARD therapy. The optimal
moment for evaluation of an early treatment response
remains to be determined. In our cohort, a protocolized
visit took place after 4 months. A DAS decrease within
an earlier period (e.g., first 3 months after diagnosis or
even earlier) might also be predictive. Further research
on timelines remains warranted.
A limitation of this study was the presence of miss-
ing DAS information at 4 months. This was partially
due to missing DAS components unrecorded during
research visits; we considered this as “missing com-
pletely at random” since missingness is based on lo-
gistical issues. DAS4 months was also missing due to
unattended 4 months of visits; this could be related
to (unmeasured) patient or disease characteristics.
Fortunately, baseline features of patients with and
without missing data did not markedly differ and sen-
sitivity analysis in which missing data was imputed
showed similar results. Another limitation is that the
choice to categorize patients in the SDFR group if the
outcome was achieved < 7 years was relatively arbi-
trary and another follow-up time might also have
been useful for categorization.
Strengths of our study are the sample size and the
long-term follow-up that allowed to use a a strict defin-
ition of SDFR. The fact that (although ≥ 1 year of follow-
up without recurrence of synovitis was required) the ac-
tual follow-up without DMARDs was much longer, 5.0
years (IQR, 2.7–9.2), shows the sustainability of this out-
come. Patients that were followed for less than 7 years
and did not achieve SDFR were categorized in the non-
SDFR group; this harbors the risk of misclassification, as
SDFR could have been achieved if 7 years of follow-up
was completed. This may also have underestimated the
SDFR prevalence in both the ACPA-negative and
ACPA-positive RA patients and might have resulted in
Verstappen et al. Arthritis Research & Therapy          (2020) 22:276 Page 9 of 11
an underestimation of the observed effect between the
SDFR and non-SDFR groups.
Conclusion
In conclusion, an early decrease in clinical disease activ-
ity in ACPA-negative RA patients seems to confine
chronicity of RA by increasing the chance of SDFR. This
suggests that the window of opportunity expands early
after diagnosis. Further pathogenetic studies in these
phases are needed to unravel the mechanisms involved
in resolution of disease persistence.
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